Reactosome

Reactosome is at the forefront of biotechnology research, dedicated to developing innovative solutions for gene therapies. With a focus on building a synthetic nucleus, Reactosome aims to enable the safest gene therapies with the largest cargo capacity. The company's groundbreaking approach involves creating synthetic nuclei that, once inside cells, operate continuously, mirroring the function of the cell's own nucleus. This method allows Reactosome to achieve significantly longer expression than RNA-based solutions, without the safety concerns associated with DNA-based approaches.

Reactosome’s primary address is in San Francisco, US, with an additional location in Heidelberg, DE. The company is committed to pushing the boundaries of biotechnology and delivering transformative therapies to patients in need. Reactosome's synthetic nucleus technology holds immense promise for revolutionizing gene therapy and addressing a wide range of diseases.

Reactosome is poised for significant growth and commercial development in the biotechnology sector. We invite the management team at Reactosome to create a customized and exclusive company showcase and product listing on our platform to further amplify their reach and impact.